International Myeloma Working Group recommendations for global myeloma care

Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial

(2013) U.-H. Mellqvist et al.   BLOOD

A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial

(2013) A. K. Stewart et al.   BLOOD

A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma

(2013) Maria T. Petrucci et al.   BRITISH JOURNAL OF HAEMATOLOGY

Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review

(2013) Josien C. Regelink et al.   BRITISH JOURNAL OF HAEMATOLOGY

New Strategies in the Treatment of Multiple Myeloma

(2013) N. C. Munshi et al.   CLINICAL CANCER RESEARCH

Validation of the Freiburg Comorbidity Index in 466 Multiple Myeloma Patients and Combination With the International Staging System Are Highly Predictive for Outcome

(2013) Martina Kleber et al.   Clinical Lymphoma Myeloma & Leukemia

Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials

(2013) S. Bringhen et al.   HAEMATOLOGICA

Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials

(2013) Pieter Sonneveld et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study

(2013) A J Jakubowiak et al.   LEUKEMIA

Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety

(2013) A Z Badros et al.   LEUKEMIA

Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma

(2013) María-Victoria Mateos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Busulfan-Based Conditioning Regimens for Multiple Myeloma

(2013) D. Reece et al.   ONCOLOGIST

Autologous Stem Cell Transplantation: An Effective Salvage Therapy in Multiple Myeloma

(2012) Emilie Lemieux et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial

(2012) M.-V. Mateos et al.   BLOOD

Have drug combinations supplanted stem cell transplantation in myeloma?

(2012) A. Palumbo et al.   BLOOD

IMWG consensus on maintenance therapy in multiple myeloma

(2012) H. Ludwig et al.   BLOOD

Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial

(2012) G. J. Morgan et al.   BLOOD

Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study

(2012) L. Rosinol et al.   BLOOD

Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma

(2012) M. Cavo et al.   BLOOD

Assessment of Vulnerability Measures and Their Effect on Survival in a Real-Life Population of Multiple Myeloma Patients Registered at Marche Region Multiple Myeloma Registry

(2012) Massimo Offidani et al.   Clinical Lymphoma Myeloma & Leukemia

Lenalidomide Plus Melphalan Without Prednisone for Previously Untreated Older Patients With Multiple Myeloma: A Phase II Trial

(2012) Darrell J. White et al.   Clinical Lymphoma Myeloma & Leukemia

Thrombosis is associated with inferior survival in multiple myeloma

(2012) S. Y. Kristinsson et al.   HAEMATOLOGICA

Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial

(2012) Pieter Sonneveld et al.   JOURNAL OF CLINICAL ONCOLOGY

Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma

(2012) Jesús F. San Miguel et al.   JOURNAL OF CLINICAL ONCOLOGY

Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project

(2012) H Avet-Loiseau et al.   LEUKEMIA

Oral antibiotic prophylaxis of early infection in multiple myeloma: a URCC/ECOG randomized phase III study

(2012) D H Vesole et al.   LEUKEMIA

The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma

(2012) M A Dimopoulos et al.   LEUKEMIA

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

(2012) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

(2012) Michel Attal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

(2012) Philip L. McCarthy et al.   NEW ENGLAND JOURNAL OF MEDICINE

European Perspective on Multiple Myeloma Treatment Strategies: Update Following Recent Congresses

(2012) H. Ludwig et al.   ONCOLOGIST

Management Strategies for Relapsed/Refractory Multiple Myeloma: Current Clinical Perspectives

(2012) Andrzej Jakubowiak   SEMINARS IN HEMATOLOGY

Second Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival

(2011) Victor H. Jimenez-Zepeda et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials

(2011) P. M. Fayers et al.   BLOOD

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)

(2011) A. Palumbo et al.   BLOOD

Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation

(2011) G. J. Morgan et al.   BLOOD

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

(2011) S. V. Rajkumar et al.   BLOOD

Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2

(2011) N. C. Munshi et al.   BLOOD

Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma

(2011) P. Moreau et al.   BLOOD

The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis

(2011) G. J. Morgan et al.   BLOOD

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation

(2011) M. Cavo et al.   BLOOD

Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation

(2011) E. Zamagni et al.   BLOOD

Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results

(2011) G. J. Morgan et al.   HAEMATOLOGICA

Genetic Factors Underlying the Risk of Thalidomide-Related Neuropathy in Patients With Multiple Myeloma

(2011) David C. Johnson et al.   JOURNAL OF CLINICAL ONCOLOGY

Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: a multicentre, randomised controlled trial

(2011) James Berenson et al.   LANCET ONCOLOGY

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

(2011) Philippe Moreau et al.   LANCET ONCOLOGY

Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis

(2011) P Kapoor et al.   LEUKEMIA

Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement

(2011) M A Dimopoulos et al.   LEUKEMIA

Management of treatment-emergent peripheral neuropathy in multiple myeloma

(2011) P G Richardson et al.   LEUKEMIA

Infectious complications in patients with multiple myeloma treated with new drug combinations containing thalidomide

(2011) Massimo Offidani et al.   LEUKEMIA & LYMPHOMA

Multiple Myeloma

(2011) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Management of Anemia in Cancer Patients: Transfusions

(2011) D. Schrijvers   ONCOLOGIST

Impact of Radiotherapy on Pain Relief and Recalcification in Plasma Cell Neoplasms

(2011) Mario Balducci et al.   STRAHLENTHERAPIE UND ONKOLOGIE

Thrombosis in Multiple Myeloma

(2011) S. Y. Kristinsson   Hematology-American Society of Hematology Education Program

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

(2010) P. G. Richardson et al.   BLOOD

Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma

(2010) H. Ludwig et al.   HAEMATOLOGICA

Analysis of 12,517 inhabitants of a Sardinian geographic isolate reveals that predispositions to thrombocytopenia and thrombocytosis are inherited traits

(2010) G. Biino et al.   HAEMATOLOGICA

Light Chain–Induced Acute Renal Failure Can Be Reversed by Bortezomib-Doxorubicin-Dexamethasone in Multiple Myeloma: Results of a Phase II Study

(2010) Heinz Ludwig et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-Term Follow-Up of Autotransplantation Trials for Multiple Myeloma: Update of Protocols Conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences

(2010) Bart Barlogie et al.   JOURNAL OF CLINICAL ONCOLOGY

Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group

(2010) Meletios A. Dimopoulos et al.   JOURNAL OF CLINICAL ONCOLOGY

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

(2010) Gareth J Morgan et al.   LANCET

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study

(2010) Michele Cavo et al.   LANCET

Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial

(2010) Annemiek Broyl et al.   LANCET ONCOLOGY

Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues

(2010) Michel Delforge et al.   LANCET ONCOLOGY

Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial

(2010) Peter Gimsing et al.   LANCET ONCOLOGY

Impact of vitamin D deficiency on the clinical presentation and prognosis of patients with newly diagnosed multiple myeloma

(2009) Alvin C. Ng et al.   AMERICAN JOURNAL OF HEMATOLOGY

Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM)

(2009) M. Roussel et al.   BLOOD

A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma

(2009) H. M. Lokhorst et al.   BLOOD

Quantitation of Serum Monoclonal Proteins: Relationship between Agarose Gel Electrophoresis and Immunonephelometry

(2009) D. L. Murray et al.   CLINICAL CHEMISTRY

Infections in Patients with Multiple Myeloma in the Era of High‐Dose Therapy and Novel Agents

(2009) Marcio Nucci et al.   CLINICAL INFECTIOUS DISEASES

Single-Agent Bortezomib in Previously Untreated Multiple Myeloma: Efficacy, Characterization of Peripheral Neuropathy, and Molecular Correlations With Response and Neuropathy

(2009) Paul G. Richardson et al.   JOURNAL OF CLINICAL ONCOLOGY

Consolidation Therapy With Low-Dose Thalidomide and Prednisolone Prolongs the Survival of Multiple Myeloma Patients Undergoing a Single Autologous Stem-Cell Transplantation Procedure

(2009) Andrew Spencer et al.   JOURNAL OF CLINICAL ONCOLOGY

Tandem Versus Single Autologous Hematopoietic Cell Transplantation for the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis

(2009) A. Kumar et al.   JNCI-Journal of the National Cancer Institute

International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma

(2009) M Dimopoulos et al.   LEUKEMIA

Management of Complications in Multiple Myeloma

(2009) Evangelos Terpos et al.   SEMINARS IN HEMATOLOGY

Evidence-Based Standards for Cancer Pain Management

(2008) Sydney M. Dy et al.   JOURNAL OF CLINICAL ONCOLOGY

Analysis of Herpes Zoster Events Among Bortezomib-Treated Patients in the Phase III APEX Study

(2008) Asher Chanan-Khan et al.   JOURNAL OF CLINICAL ONCOLOGY

The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement

(2008) M A Hussein et al.   LEUKEMIA

International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

(2008) A Dispenzieri et al.   LEUKEMIA

Pathogenesis and treatment of renal failure in multiple myeloma

(2008) M A Dimopoulos et al.   LEUKEMIA

Use of Epoetin and Darbepoetin in Patients With Cancer: 2007 American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update

(2007) J. Douglas Rizzo et al.   JOURNAL OF CLINICAL ONCOLOGY